Literature DB >> 17174121

Identification of anergic B cells within a wild-type repertoire.

Kevin T Merrell1, Robert J Benschop, Stephen B Gauld, Katja Aviszus, Debora Decote-Ricardo, Lawrence J Wysocki, John C Cambier.   

Abstract

The contribution of anergy to silencing of autoreactive B cells in physiologic settings is unknown. By comparing anergic and nonanergic immunoglobulin-transgenic mouse strains, we defined a set of surface markers that were used for presumptive identification of an anergic B cell cohort within a normal repertoire. Like anergic transgenic B cells, these physiologic anergic cells exhibited high basal intracellular free calcium and did not mobilize calcium, initiate tyrosine phosphorylation, proliferate, upregulate activation markers, or mount an immune response upon antigen-receptor stimulation. Autoreactive B cells were overrepresented in this cohort. On the basis of the frequency and lifespan of these cells, it appears that as many as 50% of newly produced B cells are destined to become anergic. In conclusion, our findings indicate that anergy is probably the primary mechanism by which autoreactive B cells are silenced. Thus maintenance of the unresponsiveness of anergic cells is critical for prevention of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17174121     DOI: 10.1016/j.immuni.2006.10.017

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  139 in total

1.  Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.

Authors:  Shannon K O'Neill; Andrew Getahun; Stephen B Gauld; Kevin T Merrell; Idan Tamir; Mia J Smith; Joseph M Dal Porto; Quan-Zhen Li; John C Cambier
Journal:  Immunity       Date:  2011-11-09       Impact factor: 31.745

Review 2.  Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.

Authors:  A Vossenkämper; P M K Lutalo; J Spencer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  The transcription factor Bright plays a role in marginal zone B lymphocyte development and autoantibody production.

Authors:  Athenia L Oldham; Cathrine A Miner; Hong-Cheng Wang; Carol F Webb
Journal:  Mol Immunol       Date:  2011-10-02       Impact factor: 4.407

Review 4.  B cells and transplantation tolerance.

Authors:  Allan D Kirk; Nicole A Turgeon; Neal N Iwakoshi
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

5.  Peripheral B cell tolerance and function in transgenic mice expressing an IgD superantigen.

Authors:  Bao Hoa Duong; Takayuki Ota; Djemel Aït-Azzouzene; Miyo Aoki-Ota; José Luis Vela; Christoph Huber; Kevin Walsh; Amanda L Gavin; David Nemazee
Journal:  J Immunol       Date:  2010-03-15       Impact factor: 5.422

Review 6.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

7.  Nur77 Links Chronic Antigen Stimulation to B Cell Tolerance by Restricting the Survival of Self-Reactive B Cells in the Periphery.

Authors:  Corey Tan; James L Mueller; Mark Noviski; John Huizar; Denise Lau; Alexandra Dubinin; Ari Molofsky; Patrick C Wilson; Julie Zikherman
Journal:  J Immunol       Date:  2019-04-08       Impact factor: 5.422

Review 8.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

9.  A role for IRF8 in B cell anergy.

Authors:  Simanta Pathak; Shibin Ma; Vipul Shukla; Runqing Lu
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

Review 10.  B cells and immunological tolerance.

Authors:  Nataly Manjarrez-Orduño; Tâm D Quách; Iñaki Sanz
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.